By Fineline Cube China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum of understanding (MoU) with Indonesia-headquartered PT Bio Farma, focusing on the development of a novel tuberculosis vaccine. This strategic partnership aims to leverage both companies’ expertise to address the pressing global health challenge of tuberculosis.
Zhifei Bio’s Expanding Tuberculosis Portfolio
Zhifei Bio’s recombinant mycobacterium tuberculosis fusion protein (EC) received marketing approval in China in April 2020, following a recommendation by the World Health Organization (WHO) for diagnosing latent tuberculosis infection. With the addition of its bovine mycobacterium vaccine, designed for individuals already infected with tuberculosis, Zhifei Bio has significantly expanded its tuberculosis prevention and treatment portfolio.
Tuberculosis: A Global Health Challenge
Tuberculosis continues to be one of the most lethal infectious diseases worldwide, highlighting the urgent need for effective vaccines and treatments. Zhifei’s recombinant mycobacterium tuberculosis fusion protein (EC) has been included in the 2022 National Reimbursement Drug List (NRDL), which came into effect from March 1, 2023. This inclusion underscores the importance of the vaccine in China’s healthcare system and its potential impact on global tuberculosis management strategies.-Fineline Info & Tech